scholarly journals The needle has been blunt for 20 years

2010 ◽  
Vol 23 (2) ◽  
pp. 330-331
Author(s):  
Brendan Silbert ◽  
David Scott ◽  
Lisbeth Evered ◽  
Paul Maruff
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Lumbar Puncture ◽  
Sampling Unit

The growing need for lumbar puncture in order to obtain cerebrospinal fluid (CSF) for the diagnosis Alzheimer's disease is becoming increasingly apparent (Herskovits and Growdon, 2010). The concept of a CSF sampling unit specializing in lumbar puncture would seem the most plausible solution. Physicians and interns are not necessarily skilled in the procedure and neurologists perform lumbar puncture rarely.

scholarly journals Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease

2018 ◽  
Vol 14 (11) ◽  
pp. 1505-1521 ◽  
Author(s):  
Leslie M. Shaw ◽  
Jalayne Arias ◽  
Kaj Blennow ◽  
Douglas Galasko ◽  
Jose Luis Molinuevo ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Lumbar Puncture ◽  
Appropriate Use Criteria ◽  
Appropriate Use

scholarly journals Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease in Subjects with Down Syndrome

2016 ◽  
Vol 55 (4) ◽  
pp. 1489-1496 ◽  
Author(s):  
María Carmona-Iragui ◽  
Telma Santos ◽  
Sebastián Videla ◽  
Susana Fernández ◽  
Bessy Benejam ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Down Syndrome ◽  
Lumbar Puncture ◽  
Cerebrospinal Fluid Biomarkers

Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A Multicenter Study in Spain

2014 ◽  
Vol 39 (4) ◽  
pp. 719-726 ◽  
Author(s):  
Daniel Alcolea ◽  
Pablo Martínez-Lage ◽  
Andrea Izagirre ◽  
Montserrat Clerigué ◽  
María Carmona-Iragui ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Lumbar Puncture ◽  
Multicenter Study ◽  
Cerebrospinal Fluid Biomarkers

DT-02-01: APPROPRIATE USE CRITERIA FOR LUMBAR PUNCTURE AND CEREBROSPINAL FLUID TESTING IN THE DIAGNOSIS OF ALZHEIMER'S DISEASE

2006 ◽  
Vol 14 (7S_Part_31) ◽  
pp. P1668-P1669
Author(s):  
Leslie M. Shaw ◽  
Jalayne J. Arias ◽  
Kaj Blennow ◽  
Doug R. Galasko ◽  
José Luis Molinuevo ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Lumbar Puncture ◽  
Appropriate Use Criteria ◽  
Appropriate Use

Asymmetrical dimethylarginine is increased in plasma and decreased in cerebrospinal fluid of patients with Alzheimer's disease

2009 ◽  
Vol 42 (05) ◽  
Author(s):  
S Arlt ◽  
F Schulze ◽  
M Eichenlaub ◽  
R Maas ◽  
K Wiedemann ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Asymmetrical Dimethylarginine

Amyloid beta in the Cerebrospinal Fluid and the Blood as a Biomarker for Alzheimer's Disease

HAPS Educator ◽  
2015 ◽  
Vol 20 (1) ◽  
pp. 38-43
Author(s):  
Brie Paddock ◽  
Kimberly Canfield ◽  
Sarah Cooper
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Amyloid Beta

scholarly journals On the design of early-phase Alzheimer’s disease clinical trials with cerebrospinal fluid tau outcomes

2021 ◽  
pp. 174077452110344
Author(s):  
Michelle M Nuño ◽  
Joshua D Grill ◽  
Daniel L Gillen ◽  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trials ◽  
Cerebrospinal Fluid ◽  
Phosphorylated Tau ◽  
Inclusion Criteria ◽  
Eligibility Criteria ◽  
Total Tau ◽  
Prodromal Alzheimer’S Disease ◽  
Study Power

Background/Aims: The focus of Alzheimer’s disease studies has shifted to earlier disease stages, including mild cognitive impairment. Biomarker inclusion criteria are often incorporated into mild cognitive impairment clinical trials to identify individuals with “prodromal Alzheimer’s disease” to ensure appropriate drug targets and enrich for participants likely to develop Alzheimer’s disease dementia. The use of these eligibility criteria may affect study power. Methods: We investigated outcome variability and study power in the setting of proof-of-concept prodromal Alzheimer’s disease trials that incorporate cerebrospinal fluid levels of total tau (t-tau) and phosphorylated (p-tau) as primary outcomes and how differing biomarker inclusion criteria affect power. We used data from the Alzheimer’s Disease Neuroimaging Initiative to model trial scenarios and to estimate the variance and within-subject correlation of total and phosphorylated tau. These estimates were then used to investigate the differences in study power for trials considering these two surrogate outcomes. Results: Patient characteristics were similar for all eligibility criteria. The lowest outcome variance and highest within-subject correlation were obtained when phosphorylated tau was used as an eligibility criterion, compared to amyloid beta or total tau, regardless of whether total tau or phosphorylated tau were used as primary outcomes. Power increased when eligibility criteria were broadened to allow for enrollment of subjects with either low amyloid beta or high phosphorylated tau. Conclusion: Specific biomarker inclusion criteria may impact statistical power in trials using total tau or phosphorylated tau as the primary outcome. In concert with other important considerations such as treatment target and population of clinical interest, these results may have implications to the integrity and efficiency of prodromal Alzheimer’s disease trial designs.

Sign in / Sign up

Export Citation Format

Share Document